

**IN THE CLAIMS:**

1. (Currently Amended) A method of treating a human patient suffering from a disease or disorder responsive to treatment with a therapeutic antibody, which comprises repeated administration of a therapeutically effective amount of a human or humanized antibody expressed and glycosylated in a suspension culture CHO cell expression system, to a patient in need thereof.
2. (Previously presented) The method of claim 1, wherein said disease or disorder is selected from the group consisting of T-cell mediated disorders, autoimmune disorders, cancer and infections diseases.
3. (Previously presented) The method of claim 2, wherein said T-cell mediated disease is selected from the group consisting of severe vasculitis, rheumatoid arthritis and systemic lupus.
4. (Withdrawn) The method of claim 2, wherein said autoimmune disorder is selected from the group consisting of multiple sclerosis, graft versus host disease, psoriasis, juvenile onset diabetes, Sjogren's disease, thyroid disease, myasthenia gravis, transplant rejection and asthma.
5. (Withdrawn) The method of claim 2, wherein said cancer is non-Hodgkin's lymphoma or multiple myeloma.
6. (Withdrawn) The method of claim 2, wherein said infectious disease is HIV or herpes.
7. (Previously presented) The method of claim 1, wherein the antibody is administered daily for up to 30 days.
8. (Previously presented) The method of claim 7, wherein the dose of antibody is between 1 to 100 mg.
9. (Currently Amended) A method of treating a human patient suffering from a disease or disorder responsive to treatment with a therapeutic antibody, which comprises administering a therapeutically effective amount of a human or humanized antibody expressed and glycosylated in a suspension culture CHO cell expression system, to a patient in need thereof, in a two-part dosing regime, wherein the antibody is administered in different doses in each part of the two-part dosing regime.
10. (Previously presented) The method of claim 9, wherein the two-part dosing regime comprises a first dosing regime, in which the antibody is administered at a dose of 1 to 5 mg for 5-10 days and a second part, in which the antibody is administered at 6-15 mg for an additional 5-10 days.
11. (New) The method of claim 1, wherein said CHO cell expression system is a spinning culture.
12. (New) The method of claim 1, wherein said suspension culture is grown in serum-free media.
13. (New) The method of claim 10, wherein said CHO cell expression system is a spinning culture.
14. (New) The method of claim 10, wherein said suspension culture is grown in serum-free media.